Floatz logo

FAPi-46

Malignant Brain Neoplasm

Jonsson Comprehensive Cancer CenterSmall moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

35 Active assets in the Malignant Brain Neoplasm cohort.

Asset / SponsorPhaseRating
Irinotecan
University of California, Davis
Phase 2BBB
Cediranib
National Cancer Institute (NCI)
Phase 2BB
Cyclophosphamide
Essen Biotech
Phase 2BB
Sorafenib
Virginia Commonwealth University
Phase 2BB
DIANHYDROGALACTITOL
Kintara Therapeutics, Inc.
Phase 2BB

View all 50 →

Same molecule, other indications

FAPi-46 is also rated in:

cholangiocarcinomaDormant
CCC
Indicative ·
55 / 100
View asset →
melanomaDormant
CCC
Indicative ·
53 / 100
View asset →
amyloidosisDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →